Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
200 shown of 6,858 total abstracts
  1. Abstract 12062026-06-01 · 14:15 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-293
    H. Borghaei, G. Curigliano · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 15902026-06-05 · 13:45 CT · S100A
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    G. Curigliano, S. Modi, H. Borghaei, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract 15062026-06-01 · 21:30 CT · E450
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-735
    J. Brahmer, S. Antonia, A. Spira · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract 16952026-06-03 · 13:45 CT · S406
    MONALEESA-898: Kisqali (ribociclib) maintenance in HR+ breast cancer
    A. Spira, S. Modi · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract 16472026-06-04 · 18:45 CT · E450
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-353
    S. Peters, H. Borghaei, M. Krop · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract 10092026-06-03 · 14:15 CT · E450
    MONALEESA-910: Kisqali (ribociclib) 1L in HR+ breast cancer
    G. Curigliano, R. Herbst, C. Robert · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract 13382026-06-05 · 13:15 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-704
    C. Saura, C. Robert · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  8. Abstract 10742026-06-03 · 14:15 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-513
    P. Schmid, R. Herbst, E. Winer, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract 14392026-06-04 · 18:30 CT · E450
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    A. Spira, H. Rugo, G. Curigliano, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract 15552026-06-02 · 13:30 CT · S406
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-314
    P. Schmid, F. Andre, S. Peters, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract 17982026-06-02 · 18:45 CT · Hall B1
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    P. Schmid, M. Krop · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract 17502026-06-04 · 21:45 CT · S100A
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-209
    L. Paz-Ares, C. Saura, S. Modi, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract 18172026-06-02 · 15:00 CT · Hall B1
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    N. Rizvi, C. Saura · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract 14112026-06-02 · 15:45 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-922
    L. Paz-Ares, J. Cortes, E. Winer, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract 17462026-06-01 · 13:30 CT · S100A
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-421
    P. Schmid, A. Spira · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract 14942026-06-01 · 14:15 CT · Hall B1
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    T. Mok, P. Schmid, J. Cortes, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract 11212026-06-02 · 14:30 CT · S406
    Long-term follow-up of Lynparza neoadjuvant for HR+ breast cancer: OlympiA-465
    H. Borghaei, L. Paz-Ares, H. Rugo, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 16902026-06-04 · 15:15 CT · Hall B1
    Long-term follow-up of Tecentriq adjuvant for TNBC: IMpower-604
    M. Reck, C. Robert · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract 11742026-06-02 · 16:15 CT · Arie Crown Theater
    ASCENT-832: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    L. Paz-Ares, P. Schmid · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  20. Abstract 15632026-06-02 · 14:15 CT · S100A
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-503
    R. Herbst, S. Tolaney, C. Saura, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  21. Abstract 17152026-06-04 · 14:30 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-855
    J. Cortes, E. Winer, S. Antonia, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  22. Abstract 17832026-06-05 · 18:30 CT · Arie Crown Theater
    MONARCH-45: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    F. Andre, J. Brahmer · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract 14042026-06-01 · 14:30 CT · S100A
    Quality of life outcomes with Trodelvy in patients with TNBC
    M. Krop, S. Modi, N. Rizvi · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  24. Abstract 12732026-06-05 · 13:45 CT · S100A
    ASCENT-136: Trodelvy (sacituzumab govitecan) neoadjuvant in TNBC
    S. Tolaney, A. Spira, P. Schmid, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract 12282026-06-02 · 15:30 CT · S406
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    F. Andre, S. Tolaney · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 10922026-06-04 · 18:15 CT · Hall B1
    Long-term follow-up of Trodelvy 3L+ for TNBC: ASCENT-151
    M.C. Garassino, J. Brahmer, E. Winer, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  27. Abstract 14682026-06-04 · 16:15 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-857 study)
    L. Paz-Ares, E. Winer · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  28. Abstract 11132026-06-02 · 16:15 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-190
    M. Reck, S. Peters, L. Paz-Ares, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract 16372026-06-04 · 20:00 CT · S100A
    MONARCH-148: Verzenio (abemaciclib) 2L in HR+ breast cancer
    P. Schmid, S. Tolaney, M. Krop · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract 12582026-06-05 · 13:45 CT · S406
    PALOMA-425: Ibrance (palbociclib) 3L+ in HR+ breast cancer
    C. Robert, H. Borghaei · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  31. Abstract 10402026-06-02 · 13:30 CT · E450
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-563
    M.C. Garassino, J. Cortes, S. Antonia, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  32. Abstract 17072026-06-03 · 21:00 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-447 study)
    H. Rugo, J. Cortes, C. Saura, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  33. Abstract 19412026-06-04 · 19:15 CT · S100A
    MONARCH-91: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    R. Herbst, S. Antonia · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  34. Abstract 15122026-06-05 · 20:15 CT · Arie Crown Theater
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    H. Borghaei, S. Modi, J. Cortes · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 17482026-06-05 · 13:45 CT · Arie Crown Theater
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-154
    M.C. Garassino, A. Spira, S. Modi, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  36. Abstract 15472026-06-02 · 19:30 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-474 study)
    N. Rizvi, J. Brahmer, P. Schmid, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  37. Abstract 13822026-06-03 · 19:45 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-75 study)
    C. Robert, E. Winer · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  38. Abstract 15432026-06-04 · 15:30 CT · Hall B1
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-646
    E. Winer, J. Brahmer, S. Antonia, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  39. Abstract 17892026-06-02 · 19:00 CT · S406
    Long-term follow-up of Keytruda adjuvant for TNBC: KEYNOTE-816
    G. Curigliano, A. Spira, S. Peters, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract 11292026-06-05 · 14:00 CT · S406
    Quality of life outcomes with Tecentriq in patients with TNBC
    G. Curigliano, E. Winer, M. Reck · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  41. Abstract 14372026-06-05 · 13:15 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-363 study)
    R. Herbst, S. Peters, C. Saura, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  42. Abstract 11852026-06-03 · 15:00 CT · Hall B1
    Long-term follow-up of Lynparza 3L+ for HR+ breast cancer: OlympiA-316
    H. Borghaei, C. Saura · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  43. Abstract 17142026-06-05 · 21:00 CT · E450
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-716
    R. Herbst, C. Robert, H. Rugo · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  44. Abstract 19362026-06-04 · 15:45 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-719 study)
    L. Paz-Ares, N. Rizvi, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  45. Abstract 19292026-06-02 · 14:00 CT · Hall B1
    IMpower-136: Tecentriq (atezolizumab) adjuvant in TNBC
    S. Tolaney, T. Mok, R. Herbst · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  46. Abstract 19832026-06-02 · 14:15 CT · E450
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-312
    C. Robert, G. Curigliano, A. Spira, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  47. Abstract 13642026-06-05 · 20:45 CT · S100A
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    E. Winer, J. Brahmer, A. Spira, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  48. Abstract 15242026-06-05 · 18:15 CT · S100A
    MONARCH-437: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    L. Paz-Ares, S. Tolaney, M. Reck, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  49. Abstract 14952026-06-01 · 19:45 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-99
    M. Reck, M.C. Garassino, S. Tolaney, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  50. Abstract 17242026-06-03 · 19:00 CT · Arie Crown Theater
    KEYNOTE-98: Keytruda (pembrolizumab) adjuvant in TNBC
    S. Modi, L. Paz-Ares · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  51. Abstract 14862026-06-02 · 14:15 CT · E450
    PALOMA-588: Ibrance (palbociclib) 1L in HR+ breast cancer
    R. Herbst, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  52. Abstract 13042026-06-01 · 13:30 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-23
    R. Herbst, C. Robert, S. Modi, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  53. Abstract 19042026-06-03 · 20:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-239 study)
    N. Rizvi, S. Peters, M.C. Garassino, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  54. Abstract 13842026-06-02 · 21:45 CT · S100A
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    C. Saura, G. Curigliano, M. Krop · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  55. Abstract 16852026-06-01 · 13:15 CT · E450
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-541 study)
    F. Andre, A. Spira, S. Peters, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract 12352026-06-05 · 13:45 CT · E450
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-123
    S. Antonia, M. Krop, G. Curigliano, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  57. Abstract 17222026-06-02 · 13:15 CT · Arie Crown Theater
    MONARCH-197: Verzenio (abemaciclib) 2L in HR+ breast cancer
    P. Schmid, S. Peters, E. Winer, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  58. Abstract 14932026-06-04 · 21:45 CT · Hall B1
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    E. Winer, F. Andre, M. Reck · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  59. Abstract 15682026-06-02 · 14:45 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-124
    J. Cortes, S. Modi · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  60. Abstract 15382026-06-02 · 15:30 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-675
    N. Rizvi, M.C. Garassino, T. Mok, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  61. Abstract 17872026-06-04 · 13:30 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-298 study)
    L. Paz-Ares, M.C. Garassino, M. Krop · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  62. Abstract 19462026-06-01 · 20:15 CT · E450
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-351
    M. Krop, N. Rizvi, M.C. Garassino · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  63. Abstract 15552026-06-04 · 13:00 CT · Arie Crown Theater
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-154
    S. Tolaney, M. Reck, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  64. Abstract 16912026-06-04 · 15:00 CT · Arie Crown Theater
    MONALEESA-251: Kisqali (ribociclib) 1L in HR+ breast cancer
    M. Reck, F. Andre · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  65. Abstract 11012026-06-01 · 14:45 CT · E450
    KEYNOTE-388: Keytruda (pembrolizumab) maintenance in TNBC
    J. Brahmer, M. Reck, A. Spira, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  66. Abstract 12742026-06-03 · 14:15 CT · S100A
    OlympiA-697: Lynparza (olaparib) adjuvant in HR+ breast cancer
    R. Herbst, J. Brahmer · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  67. Abstract 14902026-06-04 · 14:30 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-849
    P. Schmid, H. Rugo, J. Cortes, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  68. Abstract 10752026-06-02 · 13:00 CT · E450
    MONARCH-588: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    M. Krop, T. Mok · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  69. Abstract 12512026-06-05 · 20:15 CT · Hall B1
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-289
    S. Peters, C. Robert · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  70. Abstract 13462026-06-02 · 19:45 CT · Arie Crown Theater
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-839
    E. Winer, A. Spira, N. Rizvi, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  71. Abstract 18432026-06-02 · 14:00 CT · E450
    OlympiA-698: Lynparza (olaparib) adjuvant in HR+ breast cancer
    H. Rugo, M. Krop, C. Robert, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  72. Abstract 12072026-06-02 · 16:30 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-301
    R. Herbst, N. Rizvi, C. Saura · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  73. Abstract 12662026-06-05 · 20:30 CT · S100A
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-742 study)
    S. Modi, N. Rizvi, E. Winer, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  74. Abstract 15412026-06-03 · 14:30 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-619
    J. Cortes, S. Modi · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  75. Abstract 18052026-06-05 · 18:45 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-591
    F. Andre, H. Rugo, S. Antonia · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  76. Abstract 13702026-06-03 · 15:45 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-355 study)
    F. Andre, G. Curigliano, T. Mok, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  77. Abstract 11272026-06-05 · 21:00 CT · S100A
    MONALEESA-81: Kisqali (ribociclib) 1L in HR+ breast cancer
    P. Schmid, R. Herbst · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  78. Abstract 12422026-06-03 · 13:15 CT · Hall B1
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-261
    C. Saura, H. Borghaei, A. Spira, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  79. Abstract 10452026-06-05 · 14:15 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-786 study)
    S. Peters, M. Krop, C. Robert, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  80. Abstract 14042026-06-04 · 21:15 CT · S406
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    P. Schmid, T. Mok, S. Peters, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  81. Abstract 17952026-06-01 · 13:45 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-237
    M.C. Garassino, M. Krop · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  82. Abstract 11942026-06-04 · 13:15 CT · S100A
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-467
    N. Rizvi, C. Saura, H. Rugo, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  83. Abstract 14432026-06-02 · 20:30 CT · Hall B1
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    G. Curigliano, E. Winer · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  84. Abstract 11322026-06-05 · 15:15 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-108
    R. Herbst, M.C. Garassino · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  85. Abstract 19712026-06-02 · 16:30 CT · E450
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-767
    T. Mok, J. Brahmer · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  86. Abstract 17392026-06-01 · 19:30 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-890
    S. Peters, M. Reck, C. Robert, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  87. Abstract 19582026-06-05 · 20:15 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-275
    A. Spira, F. Andre · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  88. Abstract 15022026-06-04 · 13:45 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-539
    L. Paz-Ares, J. Brahmer, N. Rizvi, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  89. Abstract 16602026-06-02 · 15:00 CT · S406
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-842
    J. Cortes, F. Andre, H. Rugo · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  90. Abstract 10612026-06-03 · 13:15 CT · S406
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-164
    J. Cortes, R. Herbst, L. Paz-Ares, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  91. Abstract 19672026-06-02 · 13:00 CT · Arie Crown Theater
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-662
    E. Winer, C. Saura · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  92. Abstract 13382026-06-05 · 19:15 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-29
    S. Peters, H. Rugo · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  93. Abstract 17482026-06-05 · 13:30 CT · Arie Crown Theater
    MONALEESA-387: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    G. Curigliano, M.C. Garassino · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  94. Abstract 17442026-06-02 · 20:30 CT · E450
    MONARCH-127: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    R. Herbst, F. Andre, M. Krop, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  95. Abstract 12282026-06-02 · 18:30 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-48
    C. Saura, H. Rugo, J. Cortes · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  96. Abstract 16782026-06-02 · 16:45 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-291
    T. Mok, P. Schmid, S. Peters · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  97. Abstract 11792026-06-01 · 13:00 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-880
    S. Antonia, M. Reck · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  98. Abstract 12432026-06-04 · 13:45 CT · Hall B1
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-998
    S. Antonia, E. Winer, M. Reck, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  99. Abstract 11972026-06-04 · 14:00 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-43 study)
    S. Modi, P. Schmid, G. Curigliano, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  100. Abstract 16172026-06-05 · 15:15 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-345
    J. Brahmer, M. Krop, J. Cortes, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  101. Abstract 12802026-06-02 · 13:00 CT · S100A
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-747
    F. Andre, E. Winer · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  102. Abstract 18412026-06-04 · 21:15 CT · Hall B1
    PALOMA-811: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    S. Antonia, N. Rizvi, F. Andre, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  103. Abstract 18542026-06-03 · 16:00 CT · S406
    OlympiA-238: Lynparza (olaparib) maintenance in HR+ breast cancer
    R. Herbst, J. Cortes, H. Rugo · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  104. Abstract 15342026-06-03 · 13:00 CT · Hall B1
    IMpower-306: Tecentriq (atezolizumab) 3L+ in TNBC
    M.C. Garassino, L. Paz-Ares, S. Tolaney, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  105. Abstract 13862026-06-05 · 20:30 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-509
    N. Rizvi, R. Herbst · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  106. Abstract 15022026-06-01 · 18:45 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-933 study)
    J. Brahmer, L. Paz-Ares · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  107. Abstract 13962026-06-05 · 16:00 CT · Hall B1
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-171
    J. Brahmer, M.C. Garassino, C. Robert · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  108. Abstract 12792026-06-03 · 19:30 CT · S100A
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-142 study)
    M. Reck, S. Modi, G. Curigliano, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  109. Abstract 18332026-06-05 · 15:00 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-416 study)
    S. Antonia, R. Herbst, G. Curigliano, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  110. Abstract 18292026-06-05 · 18:00 CT · S100A
    MONARCH-769: Verzenio (abemaciclib) 1L in HR+ breast cancer
    C. Saura, S. Peters, S. Antonia, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  111. Abstract 18202026-06-05 · 19:45 CT · S100A
    MONARCH-427: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    M.C. Garassino, S. Antonia, H. Borghaei, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  112. Abstract 15312026-06-04 · 16:30 CT · Arie Crown Theater
    MONARCH-26: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    M. Krop, C. Saura, P. Schmid, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  113. Abstract 19432026-06-04 · 13:30 CT · Hall B1
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-139
    R. Herbst, J. Brahmer, S. Peters, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  114. Abstract 15872026-06-02 · 18:00 CT · S406
    Long-term follow-up of Trodelvy 3L+ for TNBC: ASCENT-967
    H. Rugo, S. Peters, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  115. Abstract 15732026-06-03 · 13:00 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with TNBC
    J. Brahmer, R. Herbst, S. Antonia · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  116. Abstract 12692026-06-01 · 13:00 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-369
    S. Tolaney, M. Krop, A. Spira, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  117. Abstract 14682026-06-05 · 21:00 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-856
    E. Winer, J. Brahmer · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  118. Abstract 13582026-06-02 · 15:45 CT · S100A
    MONALEESA-895: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    M.C. Garassino, E. Winer, R. Herbst · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  119. Abstract 12122026-06-01 · 20:00 CT · E450
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-181
    H. Rugo, F. Andre, M.C. Garassino · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  120. Abstract 13822026-06-02 · 21:30 CT · E450
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-463
    P. Schmid, M.C. Garassino · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  121. Abstract 16832026-06-01 · 19:45 CT · S100A
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-467
    S. Tolaney, L. Paz-Ares · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  122. Abstract 19632026-06-03 · 13:15 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-313 study)
    T. Mok, G. Curigliano, L. Paz-Ares, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  123. Abstract 18652026-06-04 · 19:15 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-426
    J. Brahmer, L. Paz-Ares, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  124. Abstract 15632026-06-05 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-16 study)
    C. Robert, S. Tolaney · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  125. Abstract 10852026-06-04 · 14:45 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-116
    A. Spira, J. Brahmer, C. Robert · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  126. Abstract 19462026-06-05 · 18:30 CT · E450
    ASCENT-370: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    S. Tolaney, T. Mok · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  127. Abstract 14932026-06-04 · 21:30 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-688 study)
    M. Krop, E. Winer, C. Robert, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  128. Abstract 17272026-06-04 · 21:30 CT · Arie Crown Theater
    IMpower-448: Tecentriq (atezolizumab) adjuvant in TNBC
    N. Rizvi, P. Schmid · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  129. Abstract 17942026-06-01 · 21:30 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-296
    F. Andre, M. Krop · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  130. Abstract 12812026-06-01 · 19:00 CT · Hall B1
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-324
    M. Reck, J. Brahmer, A. Spira · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  131. Abstract 18562026-06-05 · 16:15 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-409
    S. Peters, H. Rugo, C. Robert · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  132. Abstract 16762026-06-03 · 21:45 CT · S100A
    MONARCH-653: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    J. Cortes, S. Tolaney, S. Antonia, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  133. Abstract 13872026-06-03 · 16:15 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-572 study)
    F. Andre, S. Peters, J. Cortes, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  134. Abstract 16302026-06-02 · 19:15 CT · E450
    ASCENT-780: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    A. Spira, M. Krop, G. Curigliano · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  135. Abstract 16422026-06-01 · 15:45 CT · S406
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-209
    R. Herbst, A. Spira · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  136. Abstract 10742026-06-03 · 19:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-414 study)
    S. Modi, S. Tolaney, P. Schmid · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  137. Abstract 14252026-06-03 · 15:00 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-900
    S. Antonia, P. Schmid, C. Saura, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  138. Abstract 16892026-06-01 · 21:15 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-636
    E. Winer, P. Schmid, L. Paz-Ares, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  139. Abstract 15942026-06-04 · 19:00 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-224
    R. Herbst, N. Rizvi, S. Antonia · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  140. Abstract 15882026-06-01 · 14:45 CT · E450
    MONALEESA-733: Kisqali (ribociclib) neoadjuvant in HR+ breast cancer
    T. Mok, E. Winer, G. Curigliano, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  141. Abstract 18022026-06-04 · 18:30 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-13
    S. Modi, F. Andre · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  142. Abstract 19972026-06-05 · 14:30 CT · S100A
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-210
    M. Reck, S. Antonia · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  143. Abstract 14122026-06-01 · 18:30 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-81
    M. Reck, L. Paz-Ares, F. Andre · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  144. Abstract 13612026-06-01 · 21:30 CT · Hall B1
    MONALEESA-544: Kisqali (ribociclib) 1L in HR+ breast cancer
    N. Rizvi, H. Rugo, R. Herbst, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  145. Abstract 11982026-06-03 · 21:00 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-872 study)
    J. Brahmer, N. Rizvi, F. Andre, et al. · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  146. Abstract 15682026-06-02 · 14:30 CT · S100A
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-273 study)
    H. Rugo, S. Antonia · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  147. Abstract 16112026-06-02 · 20:45 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-848
    J. Cortes, C. Saura · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  148. Abstract 11322026-06-01 · 16:45 CT · Hall B1
    MONARCH-756: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    S. Tolaney, J. Cortes, M. Reck, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  149. Abstract 10332026-06-03 · 18:30 CT · Hall B1
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-566
    L. Paz-Ares, J. Cortes, P. Schmid · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  150. Abstract 11832026-06-04 · 18:30 CT · Arie Crown Theater
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-609
    P. Schmid, N. Rizvi · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  151. Abstract 11492026-06-05 · 14:30 CT · Arie Crown Theater
    Long-term follow-up of Tecentriq 2L for TNBC: IMpower-922
    J. Cortes, M.C. Garassino · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  152. Abstract 19632026-06-02 · 14:30 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-928
    M. Reck, N. Rizvi, T. Mok, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  153. Abstract 18422026-06-04 · 16:45 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-541
    J. Brahmer, S. Antonia, H. Borghaei, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  154. Abstract 19302026-06-05 · 19:30 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-748 study)
    P. Schmid, G. Curigliano, E. Winer, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  155. Abstract 17252026-06-03 · 14:30 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-826
    S. Antonia, T. Mok, G. Curigliano, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  156. Abstract 13962026-06-04 · 14:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-893 study)
    R. Herbst, H. Rugo, G. Curigliano, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  157. Abstract 19532026-06-01 · 20:00 CT · S406
    KEYNOTE-755: Keytruda (pembrolizumab) 3L+ in TNBC
    M. Krop, E. Winer, S. Modi, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  158. Abstract 12002026-06-01 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-820 study)
    T. Mok, J. Cortes · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  159. Abstract 18292026-06-02 · 14:30 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-554
    C. Saura, E. Winer · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  160. Abstract 13122026-06-04 · 15:00 CT · S100A
    MONARCH-159: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    N. Rizvi, P. Schmid, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  161. Abstract 15932026-06-03 · 19:30 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-752
    M. Reck, P. Schmid, H. Rugo, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  162. Abstract 18482026-06-03 · 20:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-869 study)
    H. Borghaei, C. Robert, P. Schmid, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  163. Abstract 15182026-06-01 · 14:15 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-548
    C. Saura, H. Borghaei, S. Modi, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  164. Abstract 15662026-06-05 · 21:15 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-56
    P. Schmid, F. Andre, S. Modi · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  165. Abstract 15522026-06-03 · 16:00 CT · Arie Crown Theater
    PALOMA-460: Ibrance (palbociclib) 2L in HR+ breast cancer
    G. Curigliano, E. Winer, M. Reck · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  166. Abstract 15472026-06-01 · 13:45 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-491 study)
    R. Herbst, H. Borghaei · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  167. Abstract 19052026-06-02 · 13:30 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-148 study)
    M. Reck, S. Antonia, H. Borghaei, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  168. Abstract 10352026-06-02 · 21:45 CT · Arie Crown Theater
    Long-term follow-up of Lynparza neoadjuvant for HR+ breast cancer: OlympiA-321
    S. Peters, S. Antonia · Princess Margaret Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  169. Abstract 18872026-06-01 · 19:45 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-691
    T. Mok, N. Rizvi · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  170. Abstract 10582026-06-01 · 19:00 CT · E450
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-737
    F. Andre, M. Reck, P. Schmid, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  171. Abstract 12792026-06-03 · 13:45 CT · S100A
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-160
    H. Rugo, J. Brahmer, J. Cortes, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  172. Abstract 14502026-06-05 · 16:15 CT · Hall B1
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-955
    M.C. Garassino, N. Rizvi, C. Saura, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  173. Abstract 17462026-06-03 · 21:00 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-895
    N. Rizvi, S. Antonia, C. Robert, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  174. Abstract 15172026-06-01 · 18:15 CT · Arie Crown Theater
    IMpower-478: Tecentriq (atezolizumab) 1L in TNBC
    S. Peters, G. Curigliano, J. Brahmer · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  175. Abstract 13732026-06-03 · 20:00 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-666
    S. Antonia, J. Brahmer, E. Winer, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  176. Abstract 19342026-06-04 · 18:45 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-10 study)
    S. Antonia, M. Reck, S. Modi, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  177. Abstract 13642026-06-02 · 19:00 CT · S406
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-577
    N. Rizvi, A. Spira, C. Robert, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  178. Abstract 13902026-06-04 · 13:30 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-206
    C. Robert, N. Rizvi · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  179. Abstract 18932026-06-04 · 16:15 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-82
    C. Saura, M. Reck, P. Schmid, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  180. Abstract 15402026-06-01 · 15:30 CT · S100A
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-811
    S. Antonia, R. Herbst, P. Schmid, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  181. Abstract 18302026-06-05 · 15:45 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-525 study)
    R. Herbst, E. Winer, S. Antonia · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  182. Abstract 19542026-06-04 · 14:30 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-930
    J. Cortes, M. Krop, H. Borghaei, et al. · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  183. Abstract 13562026-06-01 · 21:30 CT · Hall B1
    PALOMA-50: Ibrance (palbociclib) 1L in HR+ breast cancer
    J. Cortes, S. Tolaney, J. Brahmer · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  184. Abstract 17062026-06-03 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-441 study)
    T. Mok, L. Paz-Ares, P. Schmid, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  185. Abstract 17822026-06-01 · 21:15 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-522
    R. Herbst, T. Mok, G. Curigliano, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  186. Abstract 15362026-06-01 · 20:30 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-547 study)
    J. Cortes, A. Spira · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  187. Abstract 14672026-06-02 · 20:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-802 study)
    S. Peters, P. Schmid, M. Krop, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  188. Abstract 13382026-06-03 · 19:15 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-382
    G. Curigliano, M. Krop, C. Saura, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  189. Abstract 10792026-06-01 · 14:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-295
    R. Herbst, C. Saura, G. Curigliano, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  190. Abstract 12182026-06-02 · 13:45 CT · S100A
    ASCENT-960: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    S. Antonia, M. Reck, E. Winer, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  191. Abstract 10992026-06-05 · 20:15 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-717
    M.C. Garassino, J. Brahmer, M. Krop, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  192. Abstract 15372026-06-02 · 21:15 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    S. Peters, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  193. Abstract 17462026-06-02 · 20:00 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-917 study)
    S. Modi, F. Andre · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  194. Abstract 14702026-06-04 · 21:45 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-874
    T. Mok, H. Rugo, C. Robert, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  195. Abstract 17122026-06-05 · 16:30 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-549
    M. Krop, S. Tolaney, H. Borghaei · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  196. Abstract 17242026-06-04 · 13:15 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-406
    J. Brahmer, A. Spira, M. Reck, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  197. Abstract 11012026-06-03 · 14:45 CT · Arie Crown Theater
    DESTINY-Breast-785: Enhertu (trastuzumab deruxtecan) 3L+ in HR+ breast cancer
    L. Paz-Ares, T. Mok, C. Robert, et al. · Karolinska Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  198. Abstract 17252026-06-05 · 21:30 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-898 study)
    E. Winer, T. Mok, A. Spira · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  199. Abstract 14172026-06-02 · 20:30 CT · S100A
    ASCENT-723: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    A. Spira, C. Robert, L. Paz-Ares, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  200. Abstract 16562026-06-05 · 16:00 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-507 study)
    J. Cortes, S. Tolaney, M.C. Garassino, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.